Susquehanna Fundamental Investments, LLC Affimed N.V. Transaction History

Susquehanna Fundamental Investments, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$1.96 - $3.32 $79,803 - $135,177	-40,716 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$3.69 - $5.65 $232,746 - $356,373	-63,075 Reduced 60.77%	40,716 $178,000
Q4 2021 Feb 14, 2022	BUY	$5.37 - $7.07 $340,291 - $448,018	63,369 Added 156.77%	103,791 $573,000
Q3 2021 Nov 15, 2021	SELL	$5.54 - $7.51 $252,867 - $342,786	-45,644 Reduced 53.03%	40,422 $250,000
Q2 2021 Aug 11, 2021	SELL	$7.78 - $11.4 $820,089 - $1.2 Million	-105,410 Reduced 55.05%	86,066 $732,000
Q1 2021 May 17, 2021	BUY	$5.12 - $8.48 $275,968 - $457,072	53,900 Added 39.18%	191,476 $1.52 Million
Q4 2020 Feb 16, 2021	BUY	$3.16 - $7.03 $7,508 - $16,703	2,376 Added 1.76%	137,576 $801,000
Q3 2020 Nov 16, 2020	BUY	$3.26 - $4.73 $43,684 - $63,382	13,400 Added 11.0%	135,200 $458,000
Q2 2020 Aug 14, 2020	BUY	$1.58 - $4.63 $192,444 - $563,934	121,800 New	121,800 $562,000

1.09M

Ticker AFMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,339,008
Market Cap $520M
Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...

Get notified when there are updates to the investment portfolio of Susquehanna Fundamental Investments, LLC, based on Form 13F filings with the SEC.

Stay updated on Susquehanna Fundamental Investments, LLC with notifications on news.